ClinicalTrials.gg
DrugBiological

Obinutuzumab clinical trials

Also written Gazyva, GA101, RO5072759 and Gazyvaro.

studies test it
172
open now
55
in phase 3
26
first study started
2007

How each study uses obinutuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the obinutuzumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
1 Nov 2013 · GAZYVA · BLA 125486 (FDA, Drugs@FDA)
European Union
22 Jul 2014 · Gazyvaro · EMEA/H/C/002799 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Obinutuzumab
145
Anti-CD20 Monoclonal Antibody R7159
21
R7159
21
huMAB(CD20)
19
Gazyva, GA101, RO5072759
3

Brand

Gazyva
62
Gazyvaro
19

Development codes

GA101
51
RO5072759
36

In one entry with another drug

Given together, or one or the other

Glofitamab + Obinutuzumab
2

Studies by the year they started

172 studies that test it; most in 2024 (18)

Studies that test obinutuzumab, by start year
YearStudies
20071
20081
20093
20101
20114
20125
20134
20145
201515
201612
201712
201813
201912
202012
202114
202210
20239
202418
202512
20269

Who runs them

Industry 42 · Other 130

Hoffmann-La Roche (24) · M.D. Anderson Cancer Center (10) · German CLL Study Group (8) · Institute of Hematology & Blood Diseases Hospital, China (8) · Genentech, Inc. (8) · Memorial Sloan Kettering Cancer Center (5) · National Cancer Institute (NCI) (4) · University of California, San Diego (4)

Often tested with

Tested in the same studies.

Venetoclax (38) · Lenalidomide (21) · Ibrutinib (19) · Acalabrutinib (16) · Zanubrutinib (14) · Bendamustine (12) · Glofitamab (8) · Rituximab (7)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 3 phase 3 studies under way

Obinutuzumab is the comparator. A study of two new drugs counts under both.

  • 1Ibrutinib · Janssen Research & Development, LLC
  • 1Venetoclax · Janssen Research & Development, LLC
  • 1Sonrotoclax · BeOne Medicines · next primary completion Feb 2032
  • 1Zanubrutinib · BeOne Medicines · next primary completion Feb 2032
  • 1Mosunetuzumab · The Lymphoma Academic Research Organisation · next primary completion Nov 2028
  • 1Lenalidomide · The Lymphoma Academic Research Organisation · next primary completion Nov 2028
Reaching primary completion within a year · 34, 4 in phase 3

Studies that test obinutuzumab, phase 3 first.

Studies

Open first, then newest update. How each study uses obinutuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 172

See all 172 studies that test obinutuzumab →

Given beside what is tested · 133 — obinutuzumab is usual care or a partner of the new treatment

Showing 20 of 133.

As the comparator · 5 — what is tested is compared with obinutuzumab

Codes

What other systems call obinutuzumab · ClinicalTrials.gg INT005485

  • MeSH (NLM) C543332obinutuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) O43472U9X8OBINUTUZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 974779Confirmed FDA, Wikidata
  • Wikidata Q389496obinutuzumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C70741ObinutuzumabOne source FDA
  • DrugBank DB08935One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.